Generic Name and Formulations:
Lincomycin 300mg/mL; soln for IV, IM, subconjunctival inj after dilution; contains benzyl alcohol 9.45mg.
Indications for LINCOCIN:
Serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Reserved for penicillin-allergic patients or for whom penicillin is inappropriate.
IV doses: infuse over ≥60mins. Serious infections: 600mg IM every 24hrs or 600mg–1g IV every 8–12hrs. More severe infections: 600mg IM every 12hrs (or more often), or doses up to max 8g/day IV have been used for life-threatening infections. Subconjunctival inj: 75mg subconjunctivally will result in ocular fluid levels of antibiotic with MICs sufficient for most susceptible pathogens. Severe renal impairment: give 25–30% of recommended dose.
<1month: not established. IV doses: infuse over ≥60mins. ≥1month: Serious infections: 10mg/kg IM every 24hrs. More severe infections: 10mg/kg IM every 12hrs or more often. Depending on severity of infection, may also give 10–20mg/kg/day IV in divided doses.
Clostridium difficile associated diarrhea.
Risk of severe colitis (may be fatal); consider C. difficile-associated diarrhea (CDAD) in all patients presenting with diarrhea after use; discontinue if CDAD suspected/confirmed or if significant diarrhea occurs. Not for treating minor bacterial or viral infections, or meningitis. History of GI disease (esp. colitis). History of asthma or significant allergies. Severe renal impairment. Hepatic dysfunction. Monitor liver, kidney, and blood counts with prolonged and high-dose therapy. Premature infants (Gasping Syndrome from benzyl alcohol). Pregnancy (Cat.C). Nursing mothers: not recommended.
Concomitant erythromycin: not recommended. May potentiate neuromuscular blocking agents.
Nausea, vomiting, diarrhea, colitis, hematologic effects (eg, neutropenia, leukopenia, agranulocytosis, thrombocytopenic purpura), rash, urticaria, vaginitis, jaundice, abnormal LFTs, azotemia, oliguria, proteinuria, cardiopulmonary arrest and hypotension with rapid IV administration, superinfection; CDAD, hypersensitivity or severe skin reactions (discontinue if occur).
Vials (2mL, 10mL)—1
Neurology Advisor Articles
- Erenumab Superior to Placebo for Reducing Migraine Disability, Improving HRQoL
- Managing Status Epilepticus in Palliative Care: Accounting for Patient and Family Experience
- Congress Passes Bill to Fight Opioid Crisis
- Physical Activity Decreases Vascular Comorbidities in Multiple Sclerosis
- Review of Factors Impacting Sport-Related Concussion Headaches
- Anodal tDCS Offers Possible Benefit for Improving Item Recall in Post-Stroke Aphasia
- Hospitalization Tied to Brain Abnormalities in Older Adults
- Spending Often Persists in High-Cost Medicare-Medicaid Eligible
- Skills-Based Intervention Did Not Cut Systolic BP After Stroke, TIA
- High Frequency of Headaches Following Dialysis Associated With BUN and Blood Pressure